We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Mereo BioPharma Group PLC | NASDAQ:MREO | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.15 | -4.60% | 3.11 | 3.01 | 3.11 | 3.31 | 3.01 | 3.30 | 835,729 | 00:44:20 |
Denise Scots-Knight, Chief Executive of Mereo, said: “Following the closing of our $70 million financing in the first half of 2020 we have focussed on executing our strategy, advancing etigilimab (“Anti-TIGIT”) for the treatment of solid tumors alongside developing our rare disease portfolio. We remain on track to initiate a Phase 1b/2 study of etigilimab (Anti-TIGIT) in combination with an anti-PD-1 in a range of solid tumor types in Q4 2020. Our rare disease portfolio includes setrusumab for osteogenesis imperfecta which we plan to partner prior to the initiation of a pivotal Phase 3 study, and alvelestat which is being investigated in an ongoing Phase 2 proof-of-concept study for alpha-1 anti-trypsin deficiency. We were also pleased to have recently announced the initiation of a Phase 1b/2 placebo-controlled study of alvelestat in COVID-19 infected patients following the scientific publications demonstrating the involvement of neutrophil elastase in COVID-19 infection pathways. We also continue to advance other discussions with potential partners to optimize the value of our broader product portfolio.”
Recent Highlights and Upcoming Milestones
Etigilimab (Anti-TIGIT) for Solid Tumors
Setrusumab for Osteogenesis Imperfecta (OI)
Alvelestat for Severe Alpha-1 Antitrypsin Deficiency (AATD)
Partnering Discussions Continue for Portfolio of Other Clinical-Stage Programs
Corporate
Financial Highlights
Conference Call InformationMereo will host a live conference call and webcast today at 8:00 a.m. EDT / 1:00 p.m. BST to discuss the Company’s financial results and provide a corporate update.
Dial-in numbers: (866) 688-2942 (U.S.) or +1 (561) 569-9224 (U.K./International)
Conference ID number: 9572439
A live and archived webcast may be accessed by visiting the Investors sections of the Company’s website at https://www.mereobiopharma.com/investors/results-reports-and-presentations/. The archived webcast will remain available on the Company's website following the live call.
About Mereo BioPharmaMereo BioPharma is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for oncology and rare diseases. Mereo's lead oncology product candidate, etigilimab ("Anti-TIGIT"), has completed a Phase 1a dose escalation clinical trial in patients with advanced solid tumors and has been evaluated in a Phase 1b study in combination with nivolumab in select tumor types. Mereo's rare disease product portfolio consists of setrusumab, which has completed a Phase 2b dose-ranging study in adults with osteogenesis imperfecta ("OI"), as well as alvelestat, which is being investigated in a Phase 2 proof-of-concept clinical trial in patients with alpha-1 antitrypsin deficiency ("AATD") and in a Phase 1b/2 clinical trial in COVID-19 respiratory disease.
Additional Information The person responsible for arranging the release of this information on behalf of the Company is Charles Sermon, General Counsel.
Forward-Looking StatementsThis Announcement contains "forward-looking statements." All statements other than statements of historical fact contained in this Announcement are forward-looking statements within the meaning of Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the United States Securities Exchange Act of 1934, as amended. Forward-looking statements usually relate to future events and anticipated revenues, earnings, cash flows or other aspects of our operations or operating results. Forward-looking statements are often identified by the words "believe," "expect," "anticipate," "plan," "intend," "foresee," "should," "would," "could," "may," "estimate," "outlook" and similar expressions, including the negative thereof. The absence of these words, however, does not mean that the statements are not forward-looking. These forward-looking statements are based on the Company's current expectations, beliefs and assumptions concerning future developments and business conditions and their potential effect on the Company. While management believes that these forward-looking statements are reasonable as and when made, there can be no assurance that future developments affecting the Company will be those that it anticipates.
All of the Company's forward-looking statements involve known and unknown risks and uncertainties (some of which are significant or beyond its control) and assumptions that could cause actual results to differ materially from the Company's historical experience and its present expectations or projections. The foregoing factors and the other risks and uncertainties that affect the Company's business, including those described in its Annual Report on Form 20-F, Reports on Form 6-K and other documents filed from time to time by the Company with the United States Securities and Exchange Commission. The Company wishes to caution you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly update or revise any of our forward-looking statements after the date they are made, whether as a result of new information, future events or otherwise, except to the extent required by law.
Mereo BioPharma Contacts:
Mereo | +44 (0)333 023 7300 |
Denise Scots-Knight, Chief Executive Officer | |
N+1 Singer (Nominated Adviser and Broker to Mereo) | +44 (0)20 7496 3081 |
Phil Davies | |
Will Goode | |
Burns McClellan (US Investor Relations Adviser to Mereo) | +1 212 213 0006 |
Lisa Burns | |
Steve Klass | |
FTI Consulting (UK Public Relations Adviser to Mereo) | +44 (0)20 3727 1000 |
Simon Conway | |
Ciara Martin | |
Investors | investors@mereobiopharma.com |
Consolidated statement of comprehensive lossfor the six months ended June 30, 2020
Notes | Six months endedJune 30, 2020Unaudited£’000 | Six months endedJune 30, 2019Unaudited£’000 | Year endedDecember 31, 2019Audited£’000 | ||||||||
Research and development expenses | (8,479 | ) | (11,918 | ) | (23,608 | ) | |||||
Administrative expenses | (8,212 | ) | (6,918 | ) | (15,909 | ) | |||||
Operating loss | (16,691 | ) | (18,836 | ) | (39,517 | ) | |||||
Net income recognised on acquisition of subsidiary | — | 1,035 | 1,035 | ||||||||
Finance income | 39 | 137 | 377 | ||||||||
Finance charge | 3 | (97,628 | ) | (998 | ) | (3,496 | ) | ||||
Loss on disposal of intangible assets | 4 | (11,302 | ) | — | — | ||||||
Net foreign exchange (loss)/gain | (519 | ) | (20 | ) | 483 | ||||||
Loss before tax | (126,101 | ) | (18,682 | ) | (41,118 | ) | |||||
Taxation | 1,482 | 2,459 | 6,274 | ||||||||
Loss for the period, attributable to equity holders of the parent | (124,619 | ) | (16,224 | ) | (34,844 | ) | |||||
Basic and diluted loss per share for the period | (1.05 | ) | (0.22 | ) | (0.39 | ) | |||||
Other comprehensive income / (loss)Items that may be subsequently reclassified to the income statement | |||||||||||
Fair value changes on investments held at fair value through OCI | 3 | 88 | — | ||||||||
Currency translation of foreign operations | 1,324 | 711 | (499 | ) | |||||||
Total comprehensive loss for the period, attributable to equity holders of the parent | (123,292 | ) | (15,425 | ) | (35,343 | ) | |||||
Consolidated balance sheetas at June 30, 2020
Notes | June 30, 2020Unaudited£’000 | June 30, 2019Unaudited£’000 | December 31, 2019Audited£’000 | ||||
Assets | |||||||
Non-current assets | |||||||
Property, plant and equipment | 11,225 | 13,100 | 11,558 | ||||
Intangible assets | 4 | 31,876 | 45,157 | 44,456 | |||
43,101 | 58,257 | 56,014 | |||||
Current assets | |||||||
Prepayments | 1,400 | 3,068 | 2,111 | ||||
R&D tax credits | 6,624 | 7,745 | 10,426 | ||||
Other taxes recoverable | — | — | 979 | ||||
Other receivables | 1,836 | 1,953 | 572 | ||||
Short-term investments | — | 7,828 | — | ||||
Cash and short-term deposits | 56,821 | 28,290 | 16,347 | ||||
66,681 | 48,884 | 30,435 | |||||
Total assets | 109,782 | 107,141 | 86,449 | ||||
Equity and liabilities | |||||||
Equity | |||||||
Issued capital | 7 | 1,016 | 294 | 294 | |||
Share premium | 7 | 161,785 | 121,684 | 121,684 | |||
Other capital reserves | 7 | 127,727 | 58,004 | 59,147 | |||
Employee Benefit Trust shares | 7 | (1,305 | ) | (1,305 | ) | (1,305 | ) |
Other reserves | 7 | 4,875 | 7,000 | 7,000 | |||
Accumulated losses | 7 | (270,681 | ) | (127,357 | ) | (146,065 | ) |
Translation reserve | 7 | 825 | 711 | (499 | ) | ||
Total equity | 24,242 | 59,031 | 40,256 | ||||
Non-current liabilities | |||||||
Provisions | 8 | 1,698 | 1,927 | 1,449 | |||
Interest-bearing loans and borrowings | 6 | 14,506 | 11,721 | 5,373 | |||
Other liabilities | 44 | 34 | 44 | ||||
Warrant liability | 9 | 35,757 | 225 | 131 | |||
Lease liability | 11,167 | 13,139 | 9,318 | ||||
63,172 | 27,046 | 16,315 | |||||
Current liabilities | |||||||
Trade and other payables | 5,489 | 6,758 | 6,352 | ||||
Accruals | 2,701 | 5,961 | 5,138 | ||||
Provisions | 8 | 31 | 334 | 309 | |||
Interest-bearing loans and borrowings | 6 | 13,254 | 8,011 | 15,139 | |||
Contingent consideration liability | — | — | 354 | ||||
Lease liability | 893 | — | 2,586 | ||||
22,298 | 21,064 | 29,878 | |||||
Total liabilities | 85,540 | 48,110 | 46,193 | ||||
Total equity and liabilities | 109,782 | 107,141 | 86,449 |
1 Year Mereo BioPharma Chart |
1 Month Mereo BioPharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions